MannKind | MNKD - Cost Of Sales


MannKind reported $39.58M in Cost of Sales for its fiscal quarter ending in March of 2026.





Cost Of Sales Change Date
Adma Biologics USD 50.4M 8.24M Dec/2025
BioCryst Pharmaceuticals USD 9.52M 7.34M Dec/2025
Eli Lilly USD 3.58B 205M Mar/2026
Halozyme Therapeutics USD 108.75M 6.6M Mar/2026
Insmed USD 49.5M 3.34M Mar/2026
Karyopharm Therapeutics USD 1.48M 35.95M Dec/2025
MacroGenics USD 10.12M 34.18M Dec/2025
MannKind USD 39.58M 5.94M Mar/2026
Merck USD 2.94B 380M Mar/2026
Minerva Neurosciences 386K 31K Jun/2024
Novavax USD 22.1M 608K Dec/2025
Novo Nordisk DKK 1.95B 10.94B Jun/2025
Pfizer USD 4.59B 1.7B Mar/2026
Sanofi EUR 3.67B 621M Mar/2026
Xencor USD 61.66M 50.95M Jun/2025